Protein phosphatase 2A (PP2A) functions as a tumor suppressor in many cancers. Cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibits PP2A proteolytic degradation of c-Myc and enhances cell growth and tumor formation in several tissues. CIP2A expression in acute myeloid leukemia (AML) and its effect on outcome of treatment were not reported in Egyptian patients. No significant difference was detected in CIP2A expression between AML and control groups (P = 0.48). However, in AML patients, those with low CIP2A expression had a longer median overall survival than those with high expression (P = 0.059). CIP2A expression was not related to the clinical and laboratory variables and did not affect response to treatment. High-CIP2A expression was associated with a trend of shorter overall survival in adult Egyptian AML patients. It might serve as a useful marker to predict poor prognosis. CIP2A may represent a potential target for cancer therapy.

中文翻译：

---

CIP2A基因表达在埃及成人急性髓系白血病患者中的预后价值

蛋白磷酸酶 2A (PP2A) 在许多癌症中充当肿瘤抑制因子。蛋白磷酸酶 2A (CIP2A) 的癌性抑制剂可抑制 c-Myc 的 PP2A 蛋白水解降解，并增强多种组织中的细胞生长和肿瘤形成。CIP2A 在急性髓性白血病 (AML) 中的表达及其对治疗结果的影响在埃及患者中未见报道。AML 组和对照组之间的 CIP2A 表达未检测到显着差异（P = 0.48）。然而，在 AML 患者中，CIP2A 低表达者的中位总生存期比高表达者长（P = 0.059）。CIP2A 表达与临床和实验室变量无关，也不影响对治疗的反应。高 CIP2A 表达与成人埃及 AML 患者总生存期较短的趋势相关。它可以作为预测不良预后的有用标志物。CIP2A 可能代表癌症治疗的潜在靶点。